Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 58
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Biol Chem ; 295(21): 7179-7192, 2020 05 22.
Artigo em Inglês | MEDLINE | ID: mdl-32299914

RESUMO

The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly neutralizing antibodies (bNAbs) that are critical for the efficacy of a prophylactic HCV vaccine. We previously showed that a cell culture-derived, disulfide-linked high-molecular-weight (HMW) form of the E2 receptor-binding domain lacking three variable regions, Δ123-HMW, elicits broad neutralizing activity against the seven major genotypes of HCV. A limitation to the use of this antigen is that it is produced only at low yields and does not have a homogeneous composition. Here, we employed a sequential reduction and oxidation strategy to efficiently refold two high-yielding monomeric E2 species, D123 and a disulfide-minimized version (D123A7), into disulfide-linked HMW-like species (Δ123r and Δ123A7r). These proteins exhibited normal reactivity to bNAbs with continuous epitopes on the neutralizing face of E2, but reduced reactivity to conformation-dependent bNAbs and nonneutralizing antibodies (non-NAbs) compared with the corresponding monomeric species. Δ123r and Δ123A7r recapitulated the immunogenic properties of cell culture-derived D123-HMW in guinea pigs. The refolded antigens elicited antibodies that neutralized homologous and heterologous HCV genotypes, blocked the interaction between E2 and its cellular receptor CD81, and targeted the AS412, AS434, and AR3 domains. Of note, antibodies directed to epitopes overlapping with those of non-NAbs were absent. The approach to E2 antigen engineering outlined here provides an avenue for the development of preventive HCV vaccine candidates that induce bNAbs at higher yield and lower cost.


Assuntos
Glicoproteínas/imunologia , Hepacivirus/imunologia , Antígenos de Hepatite/imunologia , Imunogenicidade da Vacina , Mutação de Sentido Incorreto , Vacinas contra Hepatite Viral/imunologia , Proteínas Virais/imunologia , Substituição de Aminoácidos , Animais , Anticorpos Neutralizantes/imunologia , Glicoproteínas/genética , Cobaias , Hepacivirus/genética , Anticorpos Anti-Hepatite/imunologia , Antígenos de Hepatite/genética , Humanos , Vacinas contra Hepatite Viral/genética , Proteínas Virais/genética
2.
Proc Natl Acad Sci U S A ; 115(18): 4773-4778, 2018 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-29669922

RESUMO

The enterically transmitted hepatitis E virus (HEV) adopts a unique strategy to exit cells by cloaking its capsid (encoded by the viral ORF2 gene) and circulating in the blood as "quasi-enveloped" particles. However, recent evidence suggests that the majority of the ORF2 protein present in the patient serum and supernatants of HEV-infected cell culture exists in a free form and is not associated with virus particles. The origin and biological functions of this secreted form of ORF2 (ORF2S) are unknown. Here we show that production of ORF2S results from translation initiated at the previously presumed AUG start codon for the capsid protein, whereas translation of the actual capsid protein (ORF2C) is initiated at a previously unrecognized internal AUG codon (15 codons downstream of the first AUG). The addition of 15 amino acids to the N terminus of the capsid protein creates a signal sequence that drives ORF2S secretion via the secretory pathway. Unlike ORF2C, ORF2S is glycosylated and exists as a dimer. Nonetheless, ORF2S exhibits substantial antigenic overlap with the capsid, but the epitopes predicted to bind the putative cell receptor are lost. Consistent with this, ORF2S does not block HEV cell entry but inhibits antibody-mediated neutralization. These results reveal a previously unrecognized aspect in HEV biology and shed new light on the immune evasion mechanisms and pathogenesis of this virus.


Assuntos
Epitopos/imunologia , Antígenos de Hepatite/imunologia , Vírus da Hepatite E/imunologia , Hepatite E/imunologia , Biossíntese de Proteínas/imunologia , Proteínas Virais/imunologia , Códon de Iniciação/imunologia , Epitopos/genética , Células Hep G2 , Antígenos de Hepatite/genética , Hepatite E/genética , Hepatite E/patologia , Vírus da Hepatite E/genética , Humanos , Biossíntese de Proteínas/genética , Proteínas Virais/genética
3.
J Clin Microbiol ; 58(2)2020 01 28.
Artigo em Inglês | MEDLINE | ID: mdl-31694975

RESUMO

Hepatitis E, a liver disease caused by infection with the hepatitis E virus (HEV), is a worldwide emerging disease. The diagnosis is based on the detection of viral RNA and of HEV-specific immunoglobulins (Ig). For the latter, various assays are commercially available but still lack harmonization. In this study, a Luminex-based multiplex serological assay was established that measures the presence of total IgG, IgA, and IgM antibodies, targeting a short peptide derived from the viral E2 protein. For the validation, 160 serum samples with a known HEV serostatus were used to determine the assay cutoff and accuracy. Thereby, HEV IgG- and RNA-positive sera were identified with a sensitivity of 100% and a specificity of 98% (95% confidence interval [CI], 94% to 100%). Application of the assay by retesting 514 serum samples previously characterized with different HEV-IgG or total antibody tests revealed a high level of agreement between the assays (Cohen's kappa, 0.58 to 0.99). The established method is highly sensitive and specific and can be easily implemented in a multiplex format to facilitate rapid differential diagnostics with a few microliters of sample input.


Assuntos
Anticorpos Anti-Hepatite/sangue , Hepatite E/diagnóstico , Testes Sorológicos/métodos , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Hepatite E/imunologia , Vírus da Hepatite E , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Sensibilidade e Especificidade , Proteínas do Envelope Viral/genética , Proteínas do Envelope Viral/imunologia
4.
J Gen Virol ; 98(3): 374-384, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27902325

RESUMO

Hepatitis C virus (HCV) readily establishes chronic infection, which is characterized by failure of virus-specific CD8+ T cells. HCV uses epitope mutation and T-cell exhaustion to escape from the host immune response. Previously, we engineered high-affinity T-cell receptors (HATs) targeting human immunodeficiency virus escape mutants. In this study, the affinity of a T-cell receptor specific for the HLA-A2-restricted HCV immunodominant epitope NS3 1406-1415 (KLVALGINAV) was improved from a KD of 6.6 µM to 40 pM. These HATs could also target HCV NS3 naturally occurring variants, including an escape variant vrt1 (KLVVLGINAV), with high affinities. The HATs can be used as high-affinity targeting molecules at the centre of the immune synapse for the HLA-restricted NS3 antigen. By fusing the HAT with a T-cell activation molecule, an anti-CD3 single-chain variable fragment, we constructed a molecule called high-affinity T-cell activation core (HATac), which can redirect functional CTLs possessing any specificity to recognize and kill cells presenting HCV NS3 antigens. This capability was verified with T2 cells loaded with prototype or variant peptides and HepG2 cells expressing the truncated NS3 prototype or variant proteins. The results indicate that HATac targeting the HLA-restricted NS3 antigen may provide a useful tool for circumventing immune escape mutants and T-cell exhaustion caused by HCV infection.


Assuntos
Epitopos de Linfócito T/imunologia , Hepacivirus/imunologia , Hepatite C Crônica/imunologia , Epitopos Imunodominantes/imunologia , Receptores de Antígenos de Linfócitos T/imunologia , Proteínas não Estruturais Virais/imunologia , Complexo CD3/imunologia , Epitopos de Linfócito T/genética , Variação Genética , Células HEK293 , Antígeno HLA-A2/imunologia , Células Hep G2 , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Humanos , Epitopos Imunodominantes/genética , Receptores de Antígenos de Linfócitos T/genética , Anticorpos de Cadeia Única/imunologia , Linfócitos T Citotóxicos/imunologia , Proteínas não Estruturais Virais/genética
5.
J Virol ; 89(10): 5478-90, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25740982

RESUMO

UNLABELLED: The interaction between hepatitis C virus (HCV) and cellular immune responses during very early infection is critical for disease outcome. To date, the impact of antigen-specific cellular immune responses on the evolution of the viral population establishing infection and on potential escape has not been studied. Understanding these early host-virus dynamics is important for the development of a preventative vaccine. Three subjects who were followed longitudinally from the detection of viremia preseroconversion until disease outcome were analyzed. The evolution of transmitted/founder (T/F) viruses was undertaken using deep sequencing. CD8(+) T cell responses were measured via enzyme-linked immunosorbent spot (ELISpot) assay using HLA class I-restricted T/F epitopes. T/F viruses were rapidly extinguished in all subjects associated with either viral clearance (n = 1) or replacement with viral variants leading to establishment of chronic infection (n = 2). CD8(+) T cell responses against 11 T/F epitopes were detectable by 33 to 44 days postinfection, and 5 of these epitopes had not previously been reported. These responses declined rapidly in those who became chronically infected and were maintained in the subject who cleared infection. Higher-magnitude CD8(+) T cell responses were associated with rapid development of immune escape variants at a rate of up to 0.1 per day. Rapid escape from CD8(+) T cell responses has been quantified for the first time in the early phase of primary HCV infection. These rapid escape dynamics were associated with higher-magnitude CD8(+) T cell responses. These findings raise questions regarding optimal selection of immunogens for HCV vaccine development and suggest that detailed analysis of individual epitopes may be required. IMPORTANCE: A major limitation in our detailed understanding of the role of immune response in HCV clearance has been the lack of data on very early primary infection when the transmitted viral variants successfully establish the acute infection. This study was made possible through the availability of specimens from a unique cohort of asymptomatic primary infection cases in whom the first available viremic samples were collected approximately 3 weeks postinfection and at regular intervals thereafter. The study included detailed examination of both the evolution of the viral population and the host cellular immune responses against the T/F viruses. The findings here provide the first evidence of host cellular responses targeting T/F variants and imposing a strong selective force toward viral escape. The results of this study provide useful insight on how virus escapes the host response and consequently on future analysis of vaccine-induced immunity.


Assuntos
Linfócitos T CD8-Positivos/imunologia , Hepacivirus/imunologia , Hepacivirus/patogenicidade , Hepatite C/imunologia , Hepatite C/virologia , Doença Aguda , Adulto , Sequência de Aminoácidos , Anticorpos Antivirais/sangue , Progressão da Doença , Epitopos de Linfócito T/genética , Epitopos de Linfócito T/imunologia , Evolução Molecular , Hepacivirus/genética , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Hepatite C Crônica/imunologia , Hepatite C Crônica/virologia , Interações Hospedeiro-Patógeno , Humanos , Imunidade Celular , Masculino , Mutação , Polimorfismo de Nucleotídeo Único , Seleção Genética , Fatores de Tempo , Vacinas contra Hepatite Viral/imunologia , Carga Viral , Adulto Jovem
6.
J Virol ; 89(10): 5491-501, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25741007

RESUMO

UNLABELLED: Antisera raised against the avian hepatitis E virus (HEV) capsid protein are cross-reactive with human and swine HEV capsid proteins. In this study, two monoclonal antibodies (MAbs) against the avian HEV capsid protein, namely, 3E8 and 1B5, were shown to cross-react with the swine HEV capsid protein. The motifs involved in binding both MAbs were identified and characterized using phage display biopanning, peptide synthesis, and truncated or mutated protein expression, along with indirect enzyme-linked immunosorbent assay (ELISA) and Western blotting. The results showed that the I/VPHD motif is a necessary core sequence and that P and H are two key amino acids for recognition by MAb 3E8. The VKLYM/TS motif is the minimal amino acid sequence necessary for recognition by MAb 1B5. Cross-reactivity between the two epitopes and antibodies against avian, swine, and human HEVs in sera showed that both epitopes are common to avian, swine, and human HEVs. In addition, amino acid sequence alignment of the capsid proteins revealed that the key motifs of both novel epitopes are the same in HEVs from different animal species, predicting that they may be common to HEV isolates from boars, rabbits, rats, ferrets, mongooses, deer, and camels as well. Protein modeling analysis showed that both epitopes are at least partially exposed on the surface of the HEV capsid protein. Protective capacity analysis demonstrated that the two epitopes are nonprotective against avian HEV infection in chickens. Collectively, these studies characterize two novel linear B-cell epitopes common to avian, swine, and human HEVs, which furthers the understanding of HEV capsid protein antigenic structure. IMPORTANCE: More and more evidence indicates that the host range diversity of hepatitis E virus (HEV) is a global public health concern. A better understanding of the antigenic structure of the HEV capsid protein may improve disease diagnosis and prevention. In this study, binding site mapping and localization as well as the antigenic biology of two novel linear B-cell epitopes common to several different species of HEV were characterized. These findings partially reveal the antigenic structure of the HEV capsid protein and provide potential applications for the development of diagnostics and interventions for HEV infection.


Assuntos
Proteínas do Capsídeo/imunologia , Epitopos de Linfócito B/imunologia , Vírus da Hepatite E/imunologia , Hepevirus/imunologia , Motivos de Aminoácidos , Sequência de Aminoácidos , Animais , Anticorpos Antivirais/sangue , Aves , Proteínas do Capsídeo/química , Proteínas do Capsídeo/genética , Galinhas , Reações Cruzadas , Epitopos de Linfócito B/química , Epitopos de Linfócito B/genética , Antígenos de Hepatite/química , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Hepatite E/imunologia , Hepatite E/virologia , Vírus da Hepatite E/genética , Hepatite Viral Animal/imunologia , Hepatite Viral Animal/virologia , Hepevirus/genética , Especificidade de Hospedeiro , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Conformação Proteica , Estrutura Quaternária de Proteína , Infecções por Vírus de RNA/imunologia , Infecções por Vírus de RNA/virologia , Coelhos , Ratos , Homologia de Sequência de Aminoácidos , Suínos
7.
J Virol ; 83(3): 1379-92, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19004949

RESUMO

Hepatitis B virus (HBV) expresses two structural forms of the nucleoprotein, the intracellular nucleocapsid (hepatitis core antigen [HBcAg]) and the secreted nonparticulate form (hepatitis e antigen [HBeAg]). The aim of this study was to evaluate the ability of HBcAg- and HBeAg-specific genetic immunogens to induce HBc/HBeAg-specific CD4(+)/CD8(+) T-cell immune responses and the potential to induce liver injury in HBV-transgenic (Tg) mice. Both the HBcAg- and HBeAg-specific plasmids primed comparable immune responses. Both CD4(+) and CD8(+) T cells were important for priming/effector functions of HBc/HBeAg-specific cytotoxic T-lymphocyte (CTL) responses. However, a unique two-step immunization protocol was necessary to elicit maximal CTL priming. Genetic vaccination did not prime CTLs in HBe- or HBc/HBeAg-dbl-Tg mice but elicited a weak CTL response in HBcAg-Tg mice. When HBc/HBeAg-specific CTLs were adoptively transferred into HBc-, HBe-, and HBc/HBeAg-dbl-Tg mice, the durations of the liver injury and inflammation were significantly greater in HBeAg-Tg recipient mice than in HBcAg-Tg mice. Importantly, liver injury in HBc/HBeAg-dbl-Tg mice was similar to the injury observed in HBeAg-Tg mice. Loss of HBeAg synthesis commonly occurs during chronic HBV infection; however, the mechanism of selection of HBeAg-negative variants is unknown. The finding that hepatocytes expressing wild-type HBV (containing both HBcAg and HBeAg) are more susceptible to CTL-mediated clearance than hepatocytes expressing only HBcAg suggest that the HBeAg-negative variant may have a selective advantage over wild-type HBV within the livers of patients with chronic infection during an immune response and may represent a CTL escape mutant.


Assuntos
Antígenos de Hepatite/genética , Hepatite B Crônica/imunologia , Vírus da Hepatite E/imunologia , Mutação , Transferência Adotiva , Animais , Linhagem Celular Tumoral , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Linfócitos T Citotóxicos/imunologia
8.
J Viral Hepat ; 16(3): 156-67, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19017255

RESUMO

SUMMARY: Hepatitis C virus (HCV) is a worldwide health problem. No vaccine is available against this pathogen and therapeutic treatments currently in use are of limited efficacy. In the present study, the immunogenicity of the therapeutic vaccine candidate CIGB-230, based on the mixture of pIDKE2, a plasmid expressing HCV structural antigens, with a recombinant HCV core protein, Co.120, was evaluated. CIGB-230 was administered by intramuscular injection on weeks 0, 4, 8, 12, 16 and 20 to 15 HCV-chronically infected individuals, non-responders to previous treatment with interferon (IFN) plus ribavirin. Interestingly, following the final immunization, neutralizing antibody responses against heterologous viral pseudoparticles were modified in eight individuals, including six de novo responders. In addition, 73% of vaccinees exhibited specific T cell proliferative response and T cell IFN-gamma secretory response 24 weeks after primary immunization with CIGB-230. Furthermore, 33.3% of individuals developed de novo cellular immune response against HCV core and the number of patients (46.7% at the end of treatment) with cellular immune response against more than one HCV structural antigen increased during vaccination (P = 0.046). In addition, despite persistent detection of HCV RNA, more than 40% percent of vaccinated individuals improved or stabilized liver histology, particularly reducing fibrosis, which correlated with cellular immune response against more than one HCV antigen (P = 0.0053). In conclusion, CIGB-230 is a promising candidate for effective therapeutic interventions based on its ability for enhancing the immune response in HCV chronically infected individuals.


Assuntos
Hepacivirus/imunologia , Anticorpos Anti-Hepatite C/sangue , Hepatite C Crônica/imunologia , Linfócitos T/imunologia , Vacinas de DNA/imunologia , Vacinas contra Hepatite Viral/imunologia , Adulto , Feminino , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Hepatite C Crônica/prevenção & controle , Hepatite C Crônica/virologia , Humanos , Imunização , Interferon gama/biossíntese , Ativação Linfocitária , Masculino , Pessoa de Meia-Idade , Testes de Neutralização , RNA Viral/sangue , Resultado do Tratamento , Vacinas de DNA/administração & dosagem , Vacinas de DNA/uso terapêutico , Proteínas do Core Viral/genética , Proteínas do Core Viral/imunologia , Vacinas contra Hepatite Viral/administração & dosagem , Vacinas contra Hepatite Viral/uso terapêutico , Carga Viral
9.
Science ; 274(5284): 90-4, 1996 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-8810253

RESUMO

Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. However, viroid genomes contain no open reading frames, whereas HDV RNA encodes a single protein, hepatitis delta antigen (HDAg), which is required for viral replication. A cellular gene whose product interacts with HDAg has now been identified, and this interaction was found to affect viral genomic replication in intact cells. DNA sequence analysis revealed that this protein, termed delta-interacting protein A (DIPA), is a cellular homolog of HDAg. These observations demonstrate that a host gene product can modulate HDV replication and suggest that HDV may have evolved from a primitive viroidlike RNA through capture of a cellular transcript.


Assuntos
Evolução Biológica , Proteínas de Transporte/química , Antígenos de Hepatite/química , Antígenos de Hepatite/metabolismo , Vírus Delta da Hepatite/genética , Proteínas Adaptadoras de Transdução de Sinal , Sequência de Aminoácidos , Proteínas de Transporte/genética , Proteínas de Transporte/metabolismo , Linhagem Celular , Clonagem Molecular , Genoma Viral , Antígenos de Hepatite/genética , Vírus Delta da Hepatite/fisiologia , Antígenos da Hepatite delta , Humanos , Fígado/química , Dados de Sequência Molecular , RNA Mensageiro/genética , RNA Viral/genética , Proteínas Repressoras , Alinhamento de Sequência , Transfecção , Células Tumorais Cultivadas , Viroides/genética , Replicação Viral
10.
J Immunoassay Immunochem ; 30(1): 18-39, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19117200

RESUMO

An artificial antigen composed of 12 small antigenic regions derived from the ORF2 and ORF3 HEV proteins was designed. The gene encoding for this artificial antigen was assembled from synthetic oligonucleotides by a new method called Restriction Enzyme-Assisted Ligation (REAL). The diagnostic relevance of this second generation HEV mosaic protein (HEV MA-II) was demonstrated by testing this antigen against a panel of 142 well defined anti-HEV positive and anti-HEV negative serum samples. The data obtained in this study support the substantial diagnostic potential of this HEV mosaic antigen.


Assuntos
Antígenos de Hepatite/imunologia , Vírus da Hepatite E/imunologia , Hepatite E/diagnóstico , Proteínas Recombinantes/imunologia , Proteínas Virais/imunologia , Sequência de Aminoácidos , Animais , Sequência de Bases , Anticorpos Anti-Hepatite/sangue , Anticorpos Anti-Hepatite/imunologia , Antígenos de Hepatite/genética , Hepatite E/imunologia , Humanos , Camundongos , Dados de Sequência Molecular , Oligonucleotídeos/síntese química , Engenharia de Proteínas , Proteínas Recombinantes/genética , Proteínas Virais/genética
11.
J Mol Diagn ; 20(5): 621-627, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29959023

RESUMO

Simplified, affordable tools to diagnose active hepatitis C virus (HCV) infection are needed to scale up treatment. This study evaluated the analytical performance of HCV core antigen (HCVcAg) detection in samples of plasma and dried venous blood spots (DBSs). Paired plasma and DBS samples were prepared from remnant diagnostic samples, and plasma HCV RNA and HCVcAg were quantified. Sensitivity and specificity for HCVcAg (>3 fmol/L) at two HCV RNA thresholds (≥15 and ≥3000 IU/mL) were calculated. Of 120 paired samples tested, 25 had nonquantifiable HCV RNA and 95 had quantifiable HCV RNA. The median HCV RNA level in plasma was 5.6 log10 IU/mL (interquartile range: 5.2 to 6.2). The median HCVcAg levels in plasma and DBS samples were 2.3 log10 fmol/L (interquartile range: 0.1 to 3.1) and 1.1 log10 fmol/L (interquartile range: 0.0 to 1.9), respectively. For diagnosing HCV RNA ≥3000 IU/mL, the sensitivity and specificity of HCVcAg in plasma were 97.7% (95% CI, 91%-100%) and 100% (95% CI, 87%-100%), respectively. The sensitivity and specificity of HCVcAg in DBS were 88.6% (95% CI, 80%-94%) and 97% (95% CI, 82%-100%), respectively. The data from this study demonstrate good sensitivity and specificity of HCVcAg in plasma at an HCV RNA threshold of ≥3000 IU/mL. The level of HCVcAg quantified in plasma was higher than that in DBS.


Assuntos
Bioensaio/métodos , Teste em Amostras de Sangue Seco/métodos , Hepacivirus/imunologia , Antígenos de Hepatite/sangue , Viés , Antígenos de Hepatite/genética , Humanos , RNA Viral/sangue , RNA Viral/genética , Curva ROC , Sensibilidade e Especificidade , Análise de Sequência de DNA
12.
BMC Med Genomics ; 9(Suppl 3): 69, 2016 12 05.
Artigo em Inglês | MEDLINE | ID: mdl-28117657

RESUMO

BACKGROUND: The human influenza viruses undergo rapid evolution (especially in hemagglutinin (HA), a glycoprotein on the surface of the virus), which enables the virus population to constantly evade the human immune system. Therefore, the vaccine has to be updated every year to stay effective. There is a need to characterize the evolution of influenza viruses for better selection of vaccine candidates and the prediction of pandemic strains. Studies have shown that the influenza hemagglutinin evolution is driven by the simultaneous mutations at antigenic sites. Here, we analyze simultaneous or co-occurring mutations in the HA protein of human influenza A/H3N2, A/H1N1 and B viruses to predict potential mutations, characterizing the antigenic evolution. METHODS: We obtain the rules of mutation co-occurrence using association rule mining after extracting HA1 sequences and detect co-mutation sites under strong selective pressure. Then we predict the potential drifts with specific mutations of the viruses based on the rules and compare the results with the "observed" mutations in different years. RESULTS: The sites under frequent mutations are in antigenic regions (epitopes) or receptor binding sites. CONCLUSIONS: Our study demonstrates the co-occurring site mutations obtained by rule mining can capture the evolution of influenza viruses, and confirms that cooperative interactions among sites of HA1 protein drive the influenza antigenic evolution.


Assuntos
Evolução Molecular , Vírus da Hepatite B/genética , Vírus da Influenza A Subtipo H1N1/genética , Vírus da Influenza A Subtipo H3N2/genética , Mutação , Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética , Antígenos de Hepatite/genética , Humanos , Seleção Genética
13.
FEBS Lett ; 449(1): 41-4, 1999 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-10225424

RESUMO

Hepatitis delta antigen (HDAg) is the only viral-encoded protein of the hepatitis delta virus (HDV). This protein has been extensively characterized with respect to its biochemical and functional properties. However, the molecular mechanism responsible for persistent HDV infection is not yet clear. Previously, we reported that overexpression of HDAg protects insect cells from baculovirus-induced cytolysis [Hwang, S.B. Park, K.-J. and Kim, Y.S. (1998) Biochem. Biophys. Res. Commun. 244, 652-658]. Here we report that HDAg mediates cell cycle arrest when overexpressed in recombinant baculovirus-infected insect cells. Flow cytometry analysis has shown that HDAg expression in Spodoptera frugiperda cells causes an accumulation of substantial amounts of polyploid DNA in the absence of cell division. This phenomenon may be partly responsible for the persistent infection of chronic HDV patients.


Assuntos
Antígenos de Hepatite/metabolismo , Vírus Delta da Hepatite/metabolismo , Animais , Ciclo Celular , Divisão Celular , Linhagem Celular , Sobrevivência Celular , DNA/análise , Antígenos de Hepatite/genética , Antígenos da Hepatite delta , Poliploidia , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Spodoptera/citologia , Proteínas não Estruturais Virais/genética , Proteínas não Estruturais Virais/metabolismo
14.
J Clin Virol ; 16(1): 71-5, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10680744

RESUMO

The hepatitis E virus (HEV) has a global distribution and is known to have caused large waterborne epidemics of icteric hepatitis. The transmission is primarily fecal-oral. Some reports have suggested parenteral transmission of HEV from its association to hepatitis B or hepatitis C infection, or due to the development of hepatitis E after blood transfusion. Though most of the developing countries in Asia and Africa have been shown to be endemic for HEV infection, studies in the Latin American countries have been limited to Mexico, Brazil and Venezuela. We have developed an enzyme immunoassay (EIA) for IgM and IgG antibodies to a recombinant protein containing antigenic epitopes of the ORF3 region of the HEV. This system, as well as a commercial kit that includes ORF2 and ORF3 antigenic epitopes, were used to study the prevalence of anti-HEV antibodies in a sample of Cuban blood donors, acute hepatitis cases and individuals subjected to plasmapheresis. The incidence of anti-HEV IgM was compared with other viral hepatitis markers. Our findings suggest that infections due to HEV are an important viral cause of sporadic hepatitis in Cuba, and that HEV is endemic to this region of the world.


Assuntos
Anticorpos Anti-Hepatite/sangue , Vírus da Hepatite E/imunologia , Hepatite E/epidemiologia , Adulto , Cuba/epidemiologia , Doenças Endêmicas , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Hepatite E/diagnóstico , Humanos , Técnicas Imunoenzimáticas , Incidência , Fases de Leitura Aberta , Prevalência , Proteínas Recombinantes/imunologia
16.
J Virol Methods ; 60(1): 39-46, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8795004

RESUMO

The in vitro transcription and translation coupling system has been demonstrated to be a powerful method of characterizing protein encoded by a cloned gene. Two cDNA constructs coding hepatitis D viral (HDV) antigen, small (S) and large (L) DAg, respectively, were subjected to in vitro transcription and translation to examine multimer formation ability. By using 2-D-SDS-PAGE (non-reducing and reducing) analysis, two novel characteristics of the LDAg were found: (i) the forming of a homodimer and (ii) the formation of a complex with an unidentified 11-kDa protein via a disulfide bond. These features were neither found in SDAg nor in a cysteine-negative mutant of LDAg. Based on the fact of isoprenylation occurring at the sole cysteine residue of LDAg, it is suggested that the formation of a disulfide bond of LDAg might be involved in a transition toward isoprenylation.


Assuntos
Dissulfetos , Antígenos de Hepatite/química , Vírus Delta da Hepatite/química , Cisteína , Antígenos de Hepatite/genética , Vírus Delta da Hepatite/genética , Antígenos da Hepatite delta , Humanos , Oxirredução , Biossíntese de Proteínas , Proteínas Virais/química
17.
Artigo em Inglês | MEDLINE | ID: mdl-12897963

RESUMO

To explore the approaches and mechanisms for reversing the immune tolerance in transgenic mouse, and the pathogenicity of hepatitis G virus (HGV), the promoter of phoP-activated gene (P(pagC)) of Salmonella typhimurium was used as a transcriptionally regulating element to construct an attenuated S. typhimurium expressing HGV NS3. The recombinant S. typhimurium was orally administered to HGV transgenic mice. As the results, HGV antigen in serum and liver as well as HGV mRNA in liver were decreased significantly, although the serum anti-HGV NS3 remained undetectable as the control transgenic mice. The spleen cell proliferation, in vitro HGV NS3 specific CTL, and IFN-gamma assays with the primed cultured splenocytes indicated the induction of Th1 immune responses in those administered transgenic mice. Adoptive transfer of fractionated primed spleen cells to the transgenic mice showed that T lymphocytes were responsible for, maybe through IFN-gamma, the down-regulation of HGV mRNA transcription. Histological examination found no significant inflammatory changes in liver of the transgenic mice. These findings suggested that the oral inoculation of the HGV NS3-expressed attenuated S. typhimurium driven by an in vivo-activated promoter should be a simple and effective approach for potential treatment of chronic viral infection.


Assuntos
Vírus GB C/imunologia , Antígenos de Hepatite/imunologia , Regiões Promotoras Genéticas , Salmonella typhimurium/genética , Proteínas não Estruturais Virais/imunologia , Transferência Adotiva , Animais , Citocinas/biossíntese , Antígenos de Hepatite/genética , Imunização , Imunoterapia , Ativação Linfocitária , Camundongos , Camundongos Transgênicos , RNA Helicases , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/imunologia , Serina Endopeptidases , Linfócitos T/imunologia , Proteínas não Estruturais Virais/genética
18.
Chin Med Sci J ; 19(2): 78-83, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15250239

RESUMO

OBJECTIVE: To investigate the presentation of a neutralization epitope-containing peptide antigen of hepatitis E virus (HEV) on chimeric virus-like particles (VLPs) of hepatitis B surface antigen (HBsAg). METHODS: The gene fragment corresponding to amino acids (aa) 551-607 (HEnAg) of HEV capsid protein, which contains the only neutralization epitope identified to date, was fused via a synthetic glycine linker in frame with the gene of HBsAg. The resulted fusion gene was then integrated through transformation into the genome of Pichia pastoris under the control of a methanol-induced alcohol oxidase 1 (AOX1) promoter and expressed intracellularly. The expression products in the soluble cell extracts were characterized by Western blot, ELISA, CsCl density gradient analysis, and electron microscopic visualization. RESULTS: The novel fusion protein incorporating HBsAg and the neutralization epitope-containing HEnAg was expressed successfully in Pichia pastoris with an expected molecular weight of approximately 32 kD. It was found to possess the ability to assemble into chimeric HBV/HEV VLPs with immunological physical and morphological characteristics akin to HBsAg particles. Not only did the chimeric VLPs show high activity levels in a HBsAg particle-specific ELISA but they were also strongly immunoreactive with hepatitis E (HE) positive human serum in a HEV specific ELISA, indicating that HEnAg peptide fragments were exposed on VLP surfaces and would be expected to be readily accessible by cells and molecules of the immune system. Similarity between chimeric VLPs to highly immunogenic HBsAg particles may confer good immunogenicity on surface-displayed HEnAg. CONCLUSION: The chimeric HBV/HEV VLPs produced in this study may have potential to be a recombinant HBV/HEV bivalent vaccine candidate.


Assuntos
Antígenos de Hepatite/biossíntese , Antígenos de Superfície da Hepatite B/biossíntese , Vírus da Hepatite B/imunologia , Vírus da Hepatite E/imunologia , Pichia/genética , Epitopos , Engenharia Genética , Antígenos de Hepatite/genética , Antígenos de Hepatite/imunologia , Antígenos de Superfície da Hepatite B/genética , Antígenos de Superfície da Hepatite B/imunologia , Vírus da Hepatite B/genética , Vírus da Hepatite E/genética , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/isolamento & purificação , Vacinas Sintéticas
19.
Mol Gen Mikrobiol Virusol ; (2): 29-32, 1998.
Artigo em Russo | MEDLINE | ID: mdl-9611759

RESUMO

Hepatitis delta virus antigen was isolated from a patient by reverse transcription and polymerase chain reaction. Gel-purified cDNA was cloned in E. coli expression vectors. High expression of the recombinant HDAg in bacteria was observed. The minor and major forms of HDV antigens were simultaneously expressed in bacterial strains carrying SupE mutation. A laboratory method is developed for detecting anti-HD in patients' blood. It is based on the use of minor and major forms of recombinant HDV antigen immobilized on the same membrane filter. The method can be used for creating an original highly specific test system.


Assuntos
Antígenos de Hepatite/genética , Hepatite D/diagnóstico , Vírus Delta da Hepatite/imunologia , Clonagem Molecular , Antígenos da Hepatite delta , Humanos , Proteínas Recombinantes/imunologia , Testes Sorológicos
20.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 25(3): 324-8, 2003 Jun.
Artigo em Zh | MEDLINE | ID: mdl-12905749

RESUMO

OBJECTIVE: To construct a replication-defective recombinant adenovirus expressing the ORF2 (112-660aa) antigen of hepatitis E virus (HEV) and evaluate its immunization effect in BALB/c mice by mucosal inoculation. METHODS: The HEV ORF2 gene encoding for 112-660aa was amplified from plasmid pUC-HEV and inserted into the transfer vector pTrack-CMV. The recombinant plasmid and adenoviral backbone plasmid pAdEasy-1 were co-transformed into E. coli strain BJ5183. Taking the advantage of the high efficient homologous recombination machinery presented in bacteria, the recombinant adenovirus backbone plasmid was generated in BJ5183, and then was transfected into 293 cells. Recombinant Adenoviruses were propagated in 293 cells with high titers. 8-week-old BALB/c mice were inoculated intraperitoneally and intranasally with 10(7) pfu recombinant adenovirus each on weeks 0, 3, 5, 7, 10. RESULTS: Both groups of mice induced humoral IgG immune response with the highest titers 1:1,000 and 1:10,000 each. Only the group inoculated intranasally could induce mucosal IgA immune response. CONCLUSIONS: The adenoviral recombinant can stimulate specific humoral and mucosal immune response in mice and is potentially to be used as a candidate vaccine for the treatment of HEV infection.


Assuntos
Adenovírus Humanos/genética , Antígenos de Hepatite/imunologia , Mucosa Nasal/imunologia , Proteínas Virais/imunologia , Animais , Antígenos de Hepatite/genética , Imunoglobulina A/imunologia , Imunoglobulina G/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Peritônio/imunologia , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Vacinas contra Hepatite Viral , Proteínas Virais/biossíntese , Proteínas Virais/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA